The Warning-Letter Waves

Last updated: October 18, 2026

The FDA’s main tool against the peptide gray market, short of criminal referral, is the warning letter: a formal notice that a seller’s products are unapproved drugs being marketed in violation of federal law. Letters are regulatory notices stating the agency’s position — they are not court findings. But they create the record on which later prosecutions, like Paradigm Peptides, are built. Paradigm itself received letters in 2020 and 2022 before its owner went to prison.

How to read this tracker: convictions and sentences are court record. An indictment is an allegation only — the accused is presumed innocent unless convicted. FDA warning letters are regulatory notices describing the agency's position, not court findings. Nothing on these pages is medical advice, and none of the products discussed are FDA-approved.

Wave One — December 2024

Xcel Peptides
SwissChems
Summit Research
Prime Peptides

Wave Two — February 2025

USA Peptide

Wave Three — August 24, 2026

Royal Peptides
Peptide Partners
NuScience
Peak Performance
Tex Peptides

The Agency’s Theory

Across the waves, the FDA’s argument is consistent: a “research use only” label does not control the analysis. Intended use is proven by conduct — publishing dosing guides and calculators, selling bacteriostatic water and other injection supplies alongside the compounds, and marketing benefits to consumers. On that record, the agency treats the products as unapproved drugs intended for human use, full stop.

Warned — and Still Advertising

Enforcement attention has not emptied the market. Public Citizen found that 11 of 14 sellers who received FDA warning letters over retatrutide — an experimental compound that has never been approved anywhere — were still advertising it months later. The letters, in other words, are the beginning of the process, not the end. Sellers who ignore them are building the paper trail for the next Paradigm-style case.

The Wider Enforcement Picture

No standalone FTC action exists. Despite frequent claims online, peptide enforcement is FDA/DOJ plus private litigation — do not let anyone tell you the FTC has blessed or banned anything here.
Eli Lilly filed six lawsuits in August 2026 against sellers trading on its GLP-1 brands and has referred more than 200 sellers for enforcement.
State attorneys general have petitioned over counterfeit peptides (40+ states), and a separate 20-state letter led by Alabama AG Marshall (September 18, 2026) targeted Chinese suppliers.
Border seizures are running in parallel: roughly 130,000 vials seized by CBP between October 2025 and August 2026.

Part of the Peptide Gray Market tracker. Sources: FDA warning letters; Public Citizen; case reporting compiled October 18, 2026.

Watch the Coverage

I dug a secret underground bunker using ONLY a spoon...